Please login to the form below

Not currently logged in
Email:
Password:

Former Pfizer CEO Henry McKinnell appointed CEO of Optimer

Replaces Pedro Lichtinger who is latest to leave amid compliance investigations

Henry McKinnell, OptimerOptimer Pharmaceuticals has appointed the company's chairman and former CEO of Pfizer Dr Henry 'Hank' McKinnell to CEO.

Dr McKinnell (pictured right) will replace Pedro Lichtinger, who has been president and CEO of US biopharma Optimer since May 2010.

Lichtinger steps down as the company continues to be subject to investigations by US authorities into compliance issues.

The company's independent directors recommended a series of management changes as a result of these investigations, with previous casualties including former company chairman Michael Chang – who was replaced by Dr McKinnell in April 2012 – as well as chief financial officer John Prunty and company executive Youe-Kong Shue.

Also departing alongside Lichtinger in the latest round of changes is general counsel and chief compliance officer Kurt Hartman, who will be replaced by Meredith Schaum.

Dr McKinnell, who first joined Optimer in 2011 as a director, has a strong pedigree in pharma, serving as CEO and chair of Pfizer from 2001 to 2006.

He also currently holds the positions chairman of the board of credit ratings company Moody's Corporation and chairman of the board of the Accordia Global Health Foundation. 

Commenting on his appointment as Optimer's CEO, Dr McKinnell acknowledged the company's current compliance issues as well as the 2011 launch of the company's lead product antibiotic Dificid-Dificlir (fidaxomicin).

He said: “While the board is conducting a comprehensive review of strategic alternatives to maximise shareholder value, I look forward to working with the management team to continue to increase the utilisation of Dificid.”

28th February 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics